Cargando…

A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands

Urate-lowering therapy (ULT) is a recommended life-long treatment for gout patients. However, despite these recommendations, recurrent gout attacks are commonly observed in clinical practice. The purpose of this study was to assess the levels of compliance and persistence to ULT in The Netherlands,...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, C. A., Oude Voshaar, M. A. H., Vonkeman, H. E., Krol, M., van de Laar, M. A. F. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061072/
https://www.ncbi.nlm.nih.gov/pubmed/29721712
http://dx.doi.org/10.1007/s10067-018-4127-x
_version_ 1783342144508919808
author Janssen, C. A.
Oude Voshaar, M. A. H.
Vonkeman, H. E.
Krol, M.
van de Laar, M. A. F. J.
author_facet Janssen, C. A.
Oude Voshaar, M. A. H.
Vonkeman, H. E.
Krol, M.
van de Laar, M. A. F. J.
author_sort Janssen, C. A.
collection PubMed
description Urate-lowering therapy (ULT) is a recommended life-long treatment for gout patients. However, despite these recommendations, recurrent gout attacks are commonly observed in clinical practice. The purpose of this study was to assess the levels of compliance and persistence to ULT in The Netherlands, in order to reflect on the current gout care delivered by health professionals. Anonymous prescription records were obtained from IQVIA’s Dutch retrospective longitudinal prescription database, containing ULT dispensing data for allopurinol, febuxostat, and benzbromarone from November 2013 to July 2017. Compliance to ULT was determined by calculating the proportion of days covered (PDC) over 12 months. Persistence over 12 months was evaluated by determining the time to discontinuation, without surpassing a refill gap of > 30 days. Association of PDC and persistence with age, gender, and first prescriber were examined using beta regression- and cox-regression models, respectively. There were 45,654 patients who met the inclusion criteria. Overall, 51.7% of the patients had a ULT coverage of ≥ 80% of the days in 1 year (PDC ≥ 0.80), and 42.7% of the patients were still persistent after 1 year. Men, older patients, and patients whose first prescriber was a rheumatologist were more persistent and had a higher PDC. Our results show that medication adherence to ULT after 1 year is suboptimal, considering that current guidelines recommend ULT as a life-long treatment. Future studies addressing the reasons for treatment cessation and improving treatment adherence seem warranted.
format Online
Article
Text
id pubmed-6061072
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-60610722018-08-09 A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands Janssen, C. A. Oude Voshaar, M. A. H. Vonkeman, H. E. Krol, M. van de Laar, M. A. F. J. Clin Rheumatol Brief Report Urate-lowering therapy (ULT) is a recommended life-long treatment for gout patients. However, despite these recommendations, recurrent gout attacks are commonly observed in clinical practice. The purpose of this study was to assess the levels of compliance and persistence to ULT in The Netherlands, in order to reflect on the current gout care delivered by health professionals. Anonymous prescription records were obtained from IQVIA’s Dutch retrospective longitudinal prescription database, containing ULT dispensing data for allopurinol, febuxostat, and benzbromarone from November 2013 to July 2017. Compliance to ULT was determined by calculating the proportion of days covered (PDC) over 12 months. Persistence over 12 months was evaluated by determining the time to discontinuation, without surpassing a refill gap of > 30 days. Association of PDC and persistence with age, gender, and first prescriber were examined using beta regression- and cox-regression models, respectively. There were 45,654 patients who met the inclusion criteria. Overall, 51.7% of the patients had a ULT coverage of ≥ 80% of the days in 1 year (PDC ≥ 0.80), and 42.7% of the patients were still persistent after 1 year. Men, older patients, and patients whose first prescriber was a rheumatologist were more persistent and had a higher PDC. Our results show that medication adherence to ULT after 1 year is suboptimal, considering that current guidelines recommend ULT as a life-long treatment. Future studies addressing the reasons for treatment cessation and improving treatment adherence seem warranted. Springer London 2018-05-02 2018 /pmc/articles/PMC6061072/ /pubmed/29721712 http://dx.doi.org/10.1007/s10067-018-4127-x Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Brief Report
Janssen, C. A.
Oude Voshaar, M. A. H.
Vonkeman, H. E.
Krol, M.
van de Laar, M. A. F. J.
A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands
title A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands
title_full A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands
title_fullStr A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands
title_full_unstemmed A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands
title_short A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands
title_sort retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in the netherlands
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061072/
https://www.ncbi.nlm.nih.gov/pubmed/29721712
http://dx.doi.org/10.1007/s10067-018-4127-x
work_keys_str_mv AT janssenca aretrospectiveanalysisofmedicationprescriptionrecordsfordeterminingthelevelsofcomplianceandpersistencetourateloweringtherapyforthetreatmentofgoutandhyperuricemiainthenetherlands
AT oudevoshaarmah aretrospectiveanalysisofmedicationprescriptionrecordsfordeterminingthelevelsofcomplianceandpersistencetourateloweringtherapyforthetreatmentofgoutandhyperuricemiainthenetherlands
AT vonkemanhe aretrospectiveanalysisofmedicationprescriptionrecordsfordeterminingthelevelsofcomplianceandpersistencetourateloweringtherapyforthetreatmentofgoutandhyperuricemiainthenetherlands
AT krolm aretrospectiveanalysisofmedicationprescriptionrecordsfordeterminingthelevelsofcomplianceandpersistencetourateloweringtherapyforthetreatmentofgoutandhyperuricemiainthenetherlands
AT vandelaarmafj aretrospectiveanalysisofmedicationprescriptionrecordsfordeterminingthelevelsofcomplianceandpersistencetourateloweringtherapyforthetreatmentofgoutandhyperuricemiainthenetherlands
AT janssenca retrospectiveanalysisofmedicationprescriptionrecordsfordeterminingthelevelsofcomplianceandpersistencetourateloweringtherapyforthetreatmentofgoutandhyperuricemiainthenetherlands
AT oudevoshaarmah retrospectiveanalysisofmedicationprescriptionrecordsfordeterminingthelevelsofcomplianceandpersistencetourateloweringtherapyforthetreatmentofgoutandhyperuricemiainthenetherlands
AT vonkemanhe retrospectiveanalysisofmedicationprescriptionrecordsfordeterminingthelevelsofcomplianceandpersistencetourateloweringtherapyforthetreatmentofgoutandhyperuricemiainthenetherlands
AT krolm retrospectiveanalysisofmedicationprescriptionrecordsfordeterminingthelevelsofcomplianceandpersistencetourateloweringtherapyforthetreatmentofgoutandhyperuricemiainthenetherlands
AT vandelaarmafj retrospectiveanalysisofmedicationprescriptionrecordsfordeterminingthelevelsofcomplianceandpersistencetourateloweringtherapyforthetreatmentofgoutandhyperuricemiainthenetherlands